T
Toshihiro Fukushima
Researcher at Kanazawa Medical University
Publications - 92
Citations - 2250
Toshihiro Fukushima is an academic researcher from Kanazawa Medical University. The author has contributed to research in topics: Multiple myeloma & Idarubicin. The author has an hindex of 23, co-authored 90 publications receiving 1984 citations.
Papers
More filters
Journal ArticleDOI
Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders
Yasufumi Masaki,Lingli Dong,Lingli Dong,Nozomu Kurose,Kazuko Kitagawa,Yuko Morikawa,Motohisa Yamamoto,Hiroki Takahashi,Yasuhisa Shinomura,Kohzoh Imai,Takako Saeki,Atsushi Azumi,Shinji Nakada,Eiji Sugiyama,Shoko Matsui,Tomoki Origuchi,Susumu Nishiyama,Isao Nishimori,Takayuki Nojima,Kazunori Yamada,Mitsuhiro Kawano,Yoh Zen,Masahiko Kaneko,Kana Miyazaki,Kazuo Tsubota,Katsumi Eguchi,Kouichi Tomoda,Toshioki Sawaki,Takafumi Kawanami,Masao Tanaka,Toshihiro Fukushima,Susumu Sugai,Hisanori Umehara +32 more
TL;DR: There are considerable clinical and pathological differences between IgG4+MOLPS and SS, and based on the clinical features and good response to glucocorticoids, a new clinical entity is proposed: IgG 4+MolPS.
Journal ArticleDOI
Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version
Yasufumi Masaki,Hiroshi Kawabata,Kazue Takai,Masaru Kojima,Norifumi Tsukamoto,Yasuhito Ishigaki,Nozomu Kurose,Makoto Ide,Jun Murakami,Kenji Nara,Hiroshi Yamamoto,Yoko Ozawa,Hidekazu Takahashi,Katsuhiro Miura,Tsutomu Miyauchi,Shinichirou Yoshida,Akihito Momoi,Nobuyasu Awano,Soichiro Ikushima,Yasunori Ohta,Natsue Furuta,Shino Fujimoto,Haruka Iwao Kawanami,Tomoyuki Sakai,Takafumi Kawanami,Yoshimasa Fujita,Toshihiro Fukushima,Shigeo Nakamura,Tomohiro Kinoshita,Sadao Aoki +29 more
TL;DR: The present article reports the 2015 updated diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, as formulated by Japanese research teams, based on clinicopathologic data of 28 patients with this and similar conditions.
Journal ArticleDOI
Cutoff Values of Serum IgG4 and Histopathological IgG4+ Plasma Cells for Diagnosis of Patients with IgG4-Related Disease.
Yasufumi Masaki,Nozomu Kurose,Motohisa Yamamoto,Hiroki Takahashi,Takako Saeki,Atsushi Azumi,Shinji Nakada,Shoko Matsui,Tomoki Origuchi,Susumu Nishiyama,Kazunori Yamada,Mitsuhiro Kawano,Akira Hirabayashi,Keita Fujikawa,Tomoko Sugiura,Masanobu Horikoshi,Naoto Umeda,Hiroshi Minato,Takuji Nakamura,Haruka Iwao,Akio Nakajima,Miyuki Miki,Tomoyuki Sakai,Toshioki Sawaki,Takafumi Kawanami,Yoshimasa Fujita,Masao Tanaka,Toshihiro Fukushima,K Eguchi,Susumu Sugai,Hisanori Umehara +30 more
TL;DR: Although a recent unanimous consensus of all relevant researchers in Japan recently established the diagnostic criteria for IgG4-related disease, findings such as the authors' indicate that further discussion is needed.
Journal ArticleDOI
Japanese Variant of Multicentric Castleman's Disease Associated With Serositis and Thrombocytopenia — A Report of Two Cases: Is TAFRO Syndrome (Castleman- Kojima Disease) a Distinct Clinicopathological Entity?
Yasufumi Masaki,Akio Nakajima,Haruka Iwao,Nozomu Kurose,Tomomi Sato,Takuji Nakamura,Miyuki Miki,Tomoyuki Sakai,Takafumi Kawanami,Toshioki Sawaki,Yoshimasa Fujita,Masao Tanaka,Toshihiro Fukushima,Toshiro Okazaki,Hisanori Umehara +14 more
TL;DR: Cases of TAFRO syndrome (Castleman-Kojima disease) are still rare and it is necessary to conduct multicenter clinical surveys including similar cases to reach a consensus regarding diagnostic criteria, therapeutic strategy, and pathophysiological etiology for this syndrome.
Journal ArticleDOI
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment
Masaya Okada,Jun Imagawa,Hideo Tanaka,Hirohisa Nakamae,Masayuki Hino,Kazunori Murai,Yoji Ishida,Takashi Kumagai,Seiichi Sato,Kazuteru Ohashi,Hisashi Sakamaki,Hisashi Wakita,Nobuhiko Uoshima,Yasunori Nakagawa,Yosuke Minami,Masahiro Ogasawara,Tomoharu Takeoka,Hiroshi Akasaka,Takahiko Utsumi,Naokuni Uike,Tsutomu Sato,Sachiko Ando,Kensuke Usuki,S Mizuta,Satoshi Hashino,Tetsuhiko Nomura,Masato Shikami,Hisashi Fukutani,Yokiko Ohe,Hiroshi Kosugi,Hirohiko Shibayama,Yasuhiro Maeda,Toshihiro Fukushima,Hirohito Yamazaki,Kazuo Tsubaki,Toshimasa Kukita,Yoko Adachi,Toshiki Nataduka,Hiroto Sakoda,Hisayuki Yokoyama,Takahiro Okamoto,Yukari Shirasugi,Yasushi Onishi,Masaharu Nohgawa,Satoshi Yoshihara,Satoshi Morita,Junichi Sakamoto,Shinya Kimura +47 more
TL;DR: It is suggested that discontinuation of second‐ or subsequent‐line dasatinib after a sustained DMR of ≥ 1 year is feasible, especially for patients with no history of imatinib resistance.